JP2020505356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505356A5 JP2020505356A5 JP2019538620A JP2019538620A JP2020505356A5 JP 2020505356 A5 JP2020505356 A5 JP 2020505356A5 JP 2019538620 A JP2019538620 A JP 2019538620A JP 2019538620 A JP2019538620 A JP 2019538620A JP 2020505356 A5 JP2020505356 A5 JP 2020505356A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- cyano
- nitro
- amino
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, amino Chemical group 0.000 claims description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims description 12
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims description 12
- 108010018763 Biotin carboxylase Proteins 0.000 claims description 12
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- 125000002971 oxazolyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000001425 triazolyl group Chemical group 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 claims description 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- 206010029098 Neoplasm skin Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 2
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710052275.3 | 2017-01-22 | ||
| CN201710052275 | 2017-01-22 | ||
| PCT/CN2018/073581 WO2018133858A1 (en) | 2017-01-22 | 2018-01-22 | Thienopyrimidine derivative and use thereof in medicine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505356A JP2020505356A (ja) | 2020-02-20 |
| JP2020505356A5 true JP2020505356A5 (enExample) | 2021-02-18 |
| JP7046959B2 JP7046959B2 (ja) | 2022-04-04 |
Family
ID=62908330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538620A Active JP7046959B2 (ja) | 2017-01-22 | 2018-01-22 | チエノピリミジン誘導体及び医薬におけるその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10759812B2 (enExample) |
| EP (1) | EP3571205B1 (enExample) |
| JP (1) | JP7046959B2 (enExample) |
| KR (1) | KR102577824B1 (enExample) |
| CN (1) | CN108341830B (enExample) |
| AU (1) | AU2018209006B2 (enExample) |
| CA (1) | CA3049816A1 (enExample) |
| WO (1) | WO2018133858A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018067408A2 (pt) | 2016-03-02 | 2018-12-26 | Gilead Apollo Llc | formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas |
| AU2018227588B2 (en) * | 2017-03-03 | 2021-01-21 | Gilead Sciences, Inc. | Processes for preparing ACC inhibitors and solid forms thereof |
| CN110461328A (zh) | 2017-03-28 | 2019-11-15 | 吉利德科学公司 | 治疗肝疾病的治疗组合 |
| US11186587B2 (en) | 2017-07-26 | 2021-11-30 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Compound as ACC inhibitor and use thereof |
| CA3088997A1 (en) | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| CN109810085B (zh) * | 2019-04-19 | 2019-07-19 | 上海皓元生物医药科技有限公司 | Acc抑制剂及其中间体的制备方法 |
| CN111848678A (zh) * | 2019-04-30 | 2020-10-30 | 正大天晴药业集团股份有限公司 | 含磷类噻吩并嘧啶衍生物 |
| WO2021000242A1 (zh) | 2019-07-02 | 2021-01-07 | 广东东阳光药业有限公司 | 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用 |
| AR119594A1 (es) * | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| CN116472041B (zh) * | 2020-11-24 | 2024-12-06 | 正大天晴药业集团股份有限公司 | 氘修饰的噻吩并吡啶酮化合物 |
| TW202233632A (zh) * | 2021-02-07 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 噻吩并嘧啶衍生物 |
| CN117126175B (zh) * | 2022-05-26 | 2025-12-05 | 广东东阳光药业股份有限公司 | 噻吩并嘧啶类化合物的共晶及其用途 |
| TW202400151A (zh) * | 2022-05-26 | 2024-01-01 | 大陸商廣東東陽光藥業股份有限公司 | 噻吩並嘧啶類化合物的晶型及其用途 |
| CN117126174B (zh) * | 2022-05-26 | 2025-12-05 | 广东东阳光药业股份有限公司 | 噻吩并嘧啶类化合物的共晶及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19644228A1 (de) | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
| JP2009528389A (ja) | 2006-03-02 | 2009-08-06 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ａアデノシン受容体拮抗剤 |
| ES2665580T3 (es) | 2011-11-11 | 2018-04-26 | Gilead Apollo, Llc | Inhibidores de ACC y usos de los mismos |
| CN105358155A (zh) | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| MX2015015417A (es) | 2013-05-10 | 2016-06-21 | Nimbus Apollo Inc | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. |
| CA2911818A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
| WO2015003881A1 (en) | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| WO2015007451A1 (en) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| US20180021341A1 (en) * | 2015-01-09 | 2018-01-25 | Gilead Apollo, Llc | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| AU2016359626A1 (en) | 2015-11-25 | 2018-05-17 | Gilead Apollo, Llc | Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno(2,3-d)pyrimidine |
| EA201890913A1 (ru) | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | Пиразоловые соединения в качестве ингибиторов акк и их применение |
| KR20180082557A (ko) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | 트리아졸 acc 억제제 및 그의 용도 |
| EA201890949A1 (ru) | 2015-11-25 | 2018-12-28 | Джилид Аполло, Ллс | СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ |
| WO2017147161A1 (en) | 2016-02-23 | 2017-08-31 | Raju Mohan | Treatment of dermatological disorders or conditions |
| CN107698603B (zh) | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
| CN110431144B (zh) | 2017-03-24 | 2022-08-05 | 浙江海正药业股份有限公司 | 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途 |
| CN110431143B (zh) | 2017-03-24 | 2022-08-12 | 浙江海正药业股份有限公司 | 杂芳基并嘧啶酮类衍生物及其制备方法和用途 |
| CN110709402B (zh) | 2017-06-15 | 2022-05-10 | 浙江海正药业股份有限公司 | 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 |
-
2018
- 2018-01-22 WO PCT/CN2018/073581 patent/WO2018133858A1/en not_active Ceased
- 2018-01-22 US US16/476,290 patent/US10759812B2/en active Active
- 2018-01-22 KR KR1020197024406A patent/KR102577824B1/ko active Active
- 2018-01-22 CN CN201810057305.4A patent/CN108341830B/zh active Active
- 2018-01-22 JP JP2019538620A patent/JP7046959B2/ja active Active
- 2018-01-22 CA CA3049816A patent/CA3049816A1/en active Pending
- 2018-01-22 AU AU2018209006A patent/AU2018209006B2/en active Active
- 2018-01-22 EP EP18741820.7A patent/EP3571205B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10292968B2 (en) | Substituted heterocycles as bromodomain inhibitors | |
| JP5843861B2 (ja) | Ａｘｌ阻害剤としての薬学的に活性な化合物 | |
| CN113614080A (zh) | Kras g12c抑制剂化合物及其用途 | |
| JP2020513415A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| CN107250130B (zh) | 杂环化合物及包含其的药物组合物 | |
| RU2019118623A (ru) | Пирролопиримидины в качестве потенциаторов мвтр | |
| JP2019517487A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP2020502103A5 (enExample) | ||
| JP2010512337A5 (enExample) | ||
| US7951957B2 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| JP2019524784A5 (enExample) | ||
| RU2015143717A (ru) | 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия | |
| JP2009534408A5 (enExample) | ||
| RU2009125916A (ru) | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения | |
| RU2014141674A (ru) | 3,5-диаминопиразоловые ингибиторы киназы | |
| JP2016505512A5 (enExample) | ||
| CA2687265A1 (en) | P70 s6 kinase inhibitors | |
| JP2014508720A5 (enExample) | ||
| JP2020505398A5 (enExample) | ||
| JP2015502371A5 (enExample) | ||
| JP2019524738A (ja) | ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用 | |
| JPWO2008001929A1 (ja) | 炎症性腸疾患の処置剤 | |
| CN105050602B (zh) | 作为pi3激酶抑制剂的吡啶化合物 |